Can AI help us design better biomedical materials?

Artificial intelligence (AI) is rapidly changing the way scientists discover and design biomedical materials. In a new review published in science bulletinresearchers summarize how AI is accelerating the development of inorganic biomaterials for applications such as drug delivery, cancer therapy, anti-inflammatory therapy, and tissue engineering.

Inorganic biomaterials such as bioactive ceramics, nanozymes, and organometallic frameworks have been widely investigated for applications such as drug delivery, cancer therapy, anti-inflammatory therapy, and tissue engineering. Many of these materials have unique optical, catalytic, or structural properties that allow them to modulate reactive oxygen species, deliver therapeutic molecules, or mimic natural enzymes. However, discovering effective materials remains challenging because biological systems are highly complex and material performance depends on many interrelated factors.

“For a long time, the development of biomaterials has relied heavily on repeated experiments and empirical optimization,” the authors explain. “Researchers often need to synthesize and test a large number of candidate materials before finding one with the right biomedical properties.”

According to reviews, AI is currently being used in two main ways. The first is property prediction. Algorithms analyze existing data sets to predict how materials will behave within biological systems. This includes drug release behavior, toxicity, stability, and interactions with cells and tissues. The second is a reverse design. AI starts with a desired function, such as controlled drug release or antitumor activity, and suggests candidate material structures that can achieve that goal.

This review focuses on some important applications. In drug delivery systems, AI models can help predict how different material structures will affect drug release rates. In cancer therapy, machine learning is being used to identify nanomaterials with improved catalytic activity and ability to control reactive oxygen species. In inflammatory diseases, AI-assisted screening has enabled the discovery of nanozymes that can reduce oxidative stress and improve treatment outcomes. Tissue engineering combines AI and 3D printing techniques to optimize scaffold structures for bone regeneration and tissue repair.

The study also discusses the emerging role of generative AI models that can go beyond prediction and design to propose entirely new material structures never before observed. Large-scale computational tools such as graph neural networks and fundamental models have further expanded the searchable chemical space and enabled faster discovery of promising candidates.

Despite rapid progress, this review also points out some major challenges. One of the major issues is data quality and consistency, as experimental datasets often vary from lab to lab. Another challenge is model interpretability. This is because many AI systems function as “black boxes” that do not clearly explain their predictions. Moreover, extensive experimental validation is still required to translate the computational results into real biomedical applications.

Still, this review suggests that AI has the potential to significantly change the future of biomaterial discovery. By integrating machine learning, automated experimentation, and high-throughput screening, future research platforms may become faster, more predictable, and more autonomous.

According to the authors, the long-term vision is to establish an AI-driven materials discovery pipeline that can connect clinical needs with materials design and ultimately support the development of safer and more effective treatments.